KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Trastuzumab Deruxtecan Data Impresses at ESMO.

Cancer Discov 11(11) 2664-2665

PMID34548307
PMCID-
DOI10.1158/2159-8290.CD-NB2021-0382
发表日期2021-09-22
摘要

摘要

The DESTINY-Breast03 study, a randomized, phase III trial pitting the antibody-drug conjugates trastuzumab emtansine and trastuzumab deruxtecan against each other in HER2+ metastatic breast cancer, found remarkable improvements in efficacy and safety for the latter, newer therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。